Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

NCT02743819 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Pembrolizumab
DRUG: Ipilimumab

Sponsor

University of Chicago